Results 131 to 140 of about 19,745 (243)

ANTIPASTI: interpretable prediction of antibody binding affinity exploiting Normal Modes and Deep Learning [PDF]

arXiv
The high binding affinity of antibodies towards their cognate targets is key to eliciting effective immune responses, as well as to the use of antibodies as research and therapeutic tools. Here, we propose ANTIPASTI, a Convolutional Neural Network model that achieves state-of-the-art performance in the prediction of antibody binding affinity using as ...
arxiv  

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

Allergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy, Laura Vitale, Thomas O'Neill, Deena M. Maurer, Linda Malenchek, Andrea Crocker, Colleen Patterson, Laura Mills‐Chen, Virginia Saley, Nicole M. Antczak, James M. Boyer, Kelly M. McManus, Noe Rico Montanari, Russell A. Hammond, Joel Goldstein, Lawrence J. Thomas, Tibor Keler, Diego Alvarado   +17 more
wiley   +1 more source

Precise Antigen-Antibody Structure Predictions Enhance Antibody Development with HelixFold-Multimer [PDF]

arXiv
The accurate prediction of antigen-antibody structures is essential for advancing immunology and therapeutic development, as it helps elucidate molecular interactions that underlie immune responses. Despite recent progress with deep learning models like AlphaFold and RoseTTAFold, accurately modeling antigen-antibody complexes remains a challenge due to
arxiv  

Head‐To‐Head Comparison of Biologic Efficacy in Asthma: What Have We Learned?

Allergy, EarlyView.
ABSTRACT We performed an in‐depth appraisal of indirect head‐to‐head comparisons of biologics approved for asthma, including anti‐IL5/5Rα (mepolizumab, benralizumab), anti‐IL4Rα (dupilumab), anti‐TSLP (tezepelumab) and anti‐IgE (omalizumab), which was neither a systematic review nor a meta‐analysis.
Brian J. Lipworth, Robert Greig, Rory Chan, Chris RuiWen Kuo, Catherine Jackson   +4 more
wiley   +1 more source

AlignAb: Pareto-Optimal Energy Alignment for Designing Nature-Like Antibodies [PDF]

arXiv
We present a three-stage framework for training deep learning models specializing in antibody sequence-structure co-design. We first pre-train a language model using millions of antibody sequence data. Then, we employ the learned representations to guide the training of a diffusion model for joint optimization over both sequence and structure of ...
arxiv  

In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B‐cell lymphoma (DLBCL) cell lines with different levels of expression of CD20

British Journal of Haematology, EarlyView.
Summary Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in diffuse large B‐cell lymphoma (DLBCL), some patients fail to respond and others relapse. To begin to explore possible limitations, we compared the in vitro activity of four CD20xCD3 biosimilar BsAbs against four DLBCL cell lines with CD20 expression ...
Joshua S. Bray, Gethin R. Thomas, Victoria M. Smith, Adam Wright, Sandrine Jayne, Martin J. S. Dyer, Harriet S. Walter   +6 more
wiley   +1 more source

Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases

British Journal of Haematology, EarlyView.
Summary Glofitamab is a CD3‐CD20 bispecific antibody used to treat B‐cell non‐Hodgkin lymphoma. We describe three cases of enterocolitis occurring with glofitamab at a single institution. Similarities between cases include onset post cycle 4–5, moderately elevated faecal calprotectin, abnormal bowel avidity on positron emission tomography scan (2/3 ...
Sean McKeague, Molly Robertson, Sam van der Linde, Christine Khoo, Jonathan Segal, Sean Harrop, Adrian Minson, Andrew W. Roberts, Michael Dickinson   +8 more
wiley   +1 more source

Novel Trispecific Neutralizing Antibodies With Enhanced Potency and Breadth Against Pan-Sarbecoviruses. [PDF]

MedComm (2020)
Multispecific antibodies harness the advantages of two or more mAbs. In this study, we designed novel trispecific antibodies, Tri‐1 and Tri‐2, derived from our previously identified mAbs, PW5‐5, PW5‐535, and PW5‐570. These trispecific antibodies exhibited enhanced binding affinity and broad neutralization capacity against SARS‐CoV, SARS‐CoV‐2 variants,
Qiao R, Liu Y, Mao Q, Li J, Lu Y, Shi J, Li C, Yu J, Gong J, Wang X, Shao Y, Sun L, Zhang W, Yu H, Chu H, Wang P, Zhao X.   +16 more
europepmc   +2 more sources

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

The dark sides of the GPCR tree ‐ research progress on understudied GPCRs

British Journal of Pharmacology, EarlyView.
Abstract A large portion of the human GPCRome is still in the dark and understudied, consisting even of entire subfamilies of GPCRs such as odorant receptors, class A and C orphans, adhesion GPCRs, Frizzleds and taste receptors. However, it is undeniable that these GPCRs bring an untapped therapeutic potential that should be explored further.
Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, Antonella Di Pizio, Juliane Lehmann, Ines Liebscher, Alessandro Nicoli, Masha Y. Niv, Lior Peri, Hannes Schihada, Gunnar Schulte   +10 more
wiley   +1 more source